Reduced Buffering Nicotine Lozenges for Faster Absorption
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nicotine lozenge formulations face challenges in providing rapid and effective craving relief due to delayed nicotine absorption, leading to reduced user compliance and difficulty in managing nicotine withdrawal symptoms.
Innovation Solution
Nicotine lozenge compositions with reduced levels of alkaline buffering agents, both within and external to the master granules, optimize oral pH and enhance nicotine absorption through the oral cavity, allowing for faster release and absorption of nicotine, resulting in improved user compliance and bioequivalence to traditional lozenges.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional nicotine lozenge formulations with high levels of alkaline buffering agents are used, then nicotine absorption is enhanced, but dissolution time increases and user compliance decreases
Solution Approach 1:
The patent changes the concentration parameter of alkaline buffering agents from traditional high levels to reduced levels (approximately 5-20% of the amount used in conventional lozenges). This parameter change allows the lozenge to dissolve faster while still maintaining sufficient pH elevation for effective nicotine absorption, thereby resolving the contradiction between absorption reliability and dissolution time.
Solution Approach 2:
The patent creates a simplified version of the buffering system by using reduced levels of alkaline buffering agents that can still achieve the necessary pH effect. The extragranular buffering agents provide a simplified buffering mechanism that maintains effectiveness while reducing dissolution time, effectively copying the essential function with reduced complexity.
2Loss of time
If reduced levels of alkaline buffering agents are used, then dissolution time decreases and user compliance improves, but oral pH optimization becomes challenging
Solution Approach 1:
The patent segments the buffering agents into two locations: intragranular (within master granules) and extragranular (between granules). This segmentation allows different buffering agents to serve different functions - intragranular agents provide controlled release buffering while extragranular agents provide rapid pH elevation. This segmentation enables precise control over pH optimization despite reduced total buffering agent levels.
Solution Approach 2:
The patent applies local quality by having different buffering agent distributions in different regions of the lozenge. Intragranular buffering agents provide localized buffering within the granule structure, while extragranular buffering agents provide localized rapid pH elevation at the dissolution interface. This spatial differentiation of buffering agent properties allows optimized pH control with reduced overall buffering agent content.
3Ease of operation
If smaller lozenge size is used, then user compliance improves and dissolution time decreases, but nicotine delivery must be maintained
Solution Approach 1:
The patent changes the density and composition parameters of the lozenge formulation to maintain nicotine delivery despite reduced size. By optimizing the concentration of nicotine and buffering agents within the reduced lozenge mass, and by improving dissolution kinetics through reduced buffering agent levels, the patent achieves comparable or enhanced nicotine delivery in a smaller, more compliant lozenge format.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compositions achieve faster nicotine absorption and comparable pharmacokinetic profiles to traditional lozenges, enhancing user compliance by providing quicker craving relief and maintaining significant nicotine plasma levels, thus aiding in tobacco reduction and cessation efforts.
Implementation Method 1
The present invention relates to nicotine lozenge compositions which comprise lower levels of alkaline buffering agents than traditional nicotine containing oral dosage forms while achieving optimal and palatable oral pH
Implementation Method 2
enhancing nicotine absorption through the oral cavity
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present invention relates to nicotine lozenge compositions comprising reduced levels of buffering agents from traditional nicotine lozenges and which provide optimal oral pH and prompt nicotine absorption in a smaller, more convenient dosage form.